Glucose Control of Glucagon Secretion: There Is More to It Than $K_{ATP}$ Channels

Erik Gylfe

Diabetes is generally attributed to insulin deficiency, but it has become increasingly evident that glucagon excess accounts for many diabetic manifestations (1). In contrast to the consensus mechanisms by which hyperglycemia initiates insulin secretion, there are fundamentally different ideas regarding how glucagon release is stimulated by hyperglycemia. Current hypotheses fall into three categories. First, it is possible that glucose concentration is measured by extraneuronal sensors that feed back information to glucagon-releasing $\alpha$-cells via neurons (2,3). Second, since glucagon release is also regulated independently of neural coupling, glucose sensing may be accomplished within the pancreatic islets by $\beta$- and $\delta$-cells that control the $\alpha$-cells via paracrine release of inhibitory insulin (4), Zn$^{2+}$ (5), $\gamma$-aminobutyric acid (6), or somatostatin (7). Third, there is evidence supporting intrinsic glucose sensing by $\alpha$-cells. In this category, two hypotheses imply that glucose deficiency causes a depolarization with influx of Ca$^{2+}$ that initiates glucagon secretion by providing less energy to the electrogenic Na$^+$/K$^+$ pump (8) or by activation of a depolarizing-store-operated influx of Ca$^{2+}$ when energy is insufficient to maintain Ca$^{2+}$ in the endoplasmic reticulum (9,10). However, the most frequently cited hypothesis proposes that glucose deficit hyperpolarizes the $\alpha$-cells, relieving a depolarization-induced inactivation of ion channels involved in action potential firing and glucagon release (11). AMP-activated protein kinase may also contribute to stimulation of glucagon secretion downstream of Ca$^{2+}$ (12). Clarification of the mechanisms by which glucose regulates glucagon release should facilitate development of $\alpha$-cell–centered therapies to improve glucose homeostasis in diabetes.

The $K_{ATP}$-sensitive $K^+$ channel has been implicated in detecting glucose-induced generation of ATP in most models of glucose sensing except those with intrinsic $\alpha$-cell sensing by the Na$^+$/K$^+$ pump (8), the sarco(endo)plasmic Ca$^{2+}$ ATPase (SERCA) (9,10) or AMP-activated protein kinase (12). Using three different genetically modified mouse strains elegantly combined with pharmacological tools, Cheng-Xue et al. (13) provide convincing evidence in this issue of Diabetes that glucose can regulate glucagon secretion independently of $K_{ATP}$ channels, somatostatin, and Zn$^{2+}$. Because glucose inhibition of glucagon secretion from mouse islets is maximal at 7 mmol/L—the threshold for stimulation of insulin release (10,14)—it seems unlikely that $\beta$-cell factors should mediate inhibition in the 0–7 mmol/L glucose range. Cheng-Xue et al. confirm this idea, and also argue against a role of Zn$^{2+}$ at 10 mmol/L glucose. This concentration consequently inhibited glucagon secretion equally from control islets and those lacking the Zn$^{2+}$-accumulating transporter in the secretory granules. Somatostatin is a stronger paracrine candidate because its secretion is stimulated by the low glucose concentrations that inhibit glucagon release (10). However, Cheng-Xue et al. found that glucose-inhibited glucagon secretion was not diminished in islets from somatostatin knockout mice or after blocking somatostatin signaling with pertussis toxin, findings that were consistent with previous data (10,15). Instead, these studies showed that endogenous somatostatin has a tonic inhibitory effect but does not mediate glucose inhibition.

To evaluate the role of $K_{ATP}$ channels, Cheng-Xue et al. used depolarizing tolbutamide and hyperpolarizing diazoxide that modulate $K_{ATP}$ channel activity, as well as knockout mice lacking $K_{ATP}$ channels. Tolbutamide added in the presence of 1 mmol/L glucose mimicked the glucagonostatic effect of 7 mmol/L glucose in islets from one strain of mice, but there was no effect in the other. However, at 7 mmol/L glucose, tolbutamide was stimulatory in islets from both strains. Since tolbutamide caused pronounced stimulation of somatostatin secretion and stimulated glucagon secretion from somatostatin knockout and pertussis toxin–treated islets, the effect was attributed to a balance between direct stimulation of glucagon secretion from the $\alpha$-cell and stimulated release of inhibitory somatostatin from the $\delta$-cells. Consistent with previous data (10), the inhibitory effect of 7 mmol/L glucose on glucagon secretion remained when the $K_{ATP}$ channels were blocked with tolbutamide and even after dramatic reduction of secretion by exposure to hyperpolarizing diazoxide. Moreover, Cheng-Xue et al. found that glucose inhibits glucagon secretion in islets from $K_{ATP}$ channel knockout mice.

So why doesn't glucose reproduce the stimulatory effect of tolbutamide on glucagon secretion as it does on insulin release? Cheng-Xue et al. argue that it may be related to poor metabolism in the $\alpha$-cells, but they nevertheless provide evidence that glucose metabolism is required for inhibition of glucagon secretion. Maybe a $K_{ATP}$–mediated stimulation is too weak to overcome an inhibitory action of glucose. Although the authors refrain from discussing how sensing is accomplished, they argue that a "surprising" glucose inhibition of glucagon secretion from diazoxide-hyperpolarized $\alpha$-cell is consistent with lowering of the cytoplasmic Ca$^{2+}$ concentration (9). It is notable that this lowering is caused by glucose-stimulated Ca$^{2+}$ sequestration in the endoplasmic reticulum, a fundamental component of the store-operated hypothesis (9,10).
The evidence for K\textsubscript{ATP} channel-independent glucose sensing obtained by Cheng-Xue et al. is relevant for glucose counterregulation in the 0–7 mmol/L range. Much confusion about glucagon release may be explained by different experimental conditions if K\textsubscript{ATP} channel-dependent release of inhibitory factors from \(\beta\)-and \(\delta\)-cells contribute at higher glucose concentrations. In low glucose, the cytoplasmic Ca\textsuperscript{2+} concentration that generates hormone release remains stable in \(\beta\)-and \(\delta\)-cells but shows pronounced oscillations in \(\alpha\)-cells (16). Nevertheless, all three hormones are released at constant rates, and pulsatile secretion is only obtained in response to high glucose (17,18). Lack of gap junction coupling is probably why Ca\textsuperscript{2+} oscillations in \(\alpha\)-cells do not coordinate to produce glucagon pulses at low glucose, whereas Ca\textsuperscript{2+} oscillations induced by high glucose in \(\beta\)-cells become synchronized by such coupling (19) to generate pulsatile insulin release. Although it is not clear how somatostatin pulses become synchronized with those of insulin, K\textsubscript{ATP} channel-dependent release of inhibitory factors from \(\beta\)- and \(\delta\)-cells likely explain why glucagon pulses are in opposing phases to the pulses of insulin and somatostatin (17,18). Since average glucagon secretion often is not further inhibited when paracrine mechanisms contribute above 7 mmol/L glucose, there is likely also a stimulatory effect of high glucose in the \(\alpha\)-cell that is not necessarily K\textsubscript{ATP} channel-dependent. The hormone secretion data from ref. 17 have been recalculated as percentage of estimated secretion at 1 mmol/L glucose. Somato., somatostatin.

FIG. 1. A and B: In the 1–7 mmol/L range (G1, G7) glucose controls glucagon release via an intrinsic non-K\textsubscript{ATP} channel-dependent mechanism in \(\alpha\)-cells, and paracrine release of somatostatin from \(\delta\)-cells has only a tonic inhibitory effect. The graph showing glucose inhibition of glucagon secretion is expressed in percent of stimulated secretion at 1 mmol/L glucose (from Cheng-Xue et al.). To get an impression of the relative magnitudes of the corresponding insulin and somatostatin responses, their secretions are expressed in percent of stimulated secretion in response to 0.5 mmol/L tolbutamide. A and C: At 20 mmol/L glucose (G20) the K\textsubscript{ATP}-independent mechanism no longer stimulates glucagon secretion and the pulsatility is generated via paracrine release of inhibitory factors from \(\beta\)- and \(\delta\)-cells. The question mark indicates that a stimulatory effect of high glucose in the \(\alpha\)-cell is not necessarily K\textsubscript{ATP} channel-dependent. The hormone secretion data from ref. 17 have been recalculated as percentage of estimated secretion at 1 mmol/L glucose. Somato., somatostatin.

The evidence for K\textsubscript{ATP} channel-independent glucose sensing obtained by Cheng-Xue et al. is relevant for glucose counterregulation in the 0–7 mmol/L range. Much confusion about glucagon release may be explained by different experimental conditions if K\textsubscript{ATP} channel-dependent release of inhibitory factors from \(\beta\)- and \(\delta\)-cells contribute at higher glucose concentrations. In low glucose, the cytoplasmic Ca\textsuperscript{2+} concentration that generates hormone release remains stable in \(\beta\)-and \(\delta\)-cells but shows pronounced oscillations in \(\alpha\)-cells (16). Nevertheless, all three hormones are released at constant rates, and pulsatile secretion is only obtained in response to high glucose (17,18). Lack of gap junction coupling is probably why Ca\textsuperscript{2+} oscillations in \(\alpha\)-cells do not coordinate to produce glucagon pulses at low glucose, whereas Ca\textsuperscript{2+} oscillations induced by high glucose in \(\beta\)-cells become synchronized by such coupling (19) to generate pulsatile insulin release. Although it is not clear how somatostatin pulses become synchronized with those of insulin, K\textsubscript{ATP} channel-dependent release of inhibitory factors from \(\beta\)- and \(\delta\)-cells likely explain why glucagon pulses are in opposing phases to the pulses of insulin and somatostatin (17,18). Since average glucagon secretion often is not further inhibited when paracrine mechanisms contribute above 7 mmol/L glucose, there is likely also a stimulatory effect of high glucose in the \(\alpha\)-cell that is not necessarily K\textsubscript{ATP} channel-dependent. The hormone secretion data from ref. 17 have been recalculated as percentage of estimated secretion at 1 mmol/L glucose. Somato., somatostatin.

ACKNOWLEDGMENTS

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012;122:4–12
2. Miki T, LisB, Minami K, et al. ATP-sensitive K\textsuperscript{+} channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat Neurosci 2001;4:507–512
3. Thorens B. Brain glucose sensing and neural regulation of insulin and glucagon secretion. Diabetes Obes Metab 2011;13(Suppl. 1):82–88
4. Östenson CG. Regulation of glucagon release: effects of insulin on the pancreatic A2-cell of the guinea pig. Diabetologia 1979;17:325–330
5. Ishihara H, Maechler P, Gjinovci A, Herrera PL, Wollheim CB. Islet \(\beta\)-cell secretion determines glucagon release from neighbouring \(\alpha\)-cells. Nat Cell Biol 2003;5:330–335
6. Rorsman P, Bergrén PO, Bovik K, et al. Glucose-inhibition of glucagon secretion involves activation of GABA\textsubscript{A}-receptor chloride channels. Nature 1989;341:233–236
7. Starke A, Imamura T, Unger RH. Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration. J Clin Invest 1987;79:20–24
8. Bode IP, Weber S, Fehmann HC, Göke B. A nutrient-regulated cytosolic calcium oscillator in endocrine pancreatic glucagon-secreting cells. Pfugers Arch 1999;437:324–334
9. Liu YJ, Vieira E, Gylfe E. A store-operated mechanism determines the activity of the electrically excitable glucagon-secreting pancreatic \(\alpha\)-cell. Cell Calcium 2004;35:357–365
10. Vieira E, Salehi A, Gyfle E. Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic α cells. Diabetologia 2007;50:370–379
11. Rorsman P, Salehi SA, Abdulkader F, Braun M, MacDonald PEK. K$_{ATP}$ channels and glucose-regulated glucagon secretion. Trends Endocrinol Metab 2008;19:277–284
12. Leclerc I, Sun G, Morris C, Fernandez-Millan E, Nyirenda M, Rutter GA. AMP-activated protein kinase regulates glucagon secretion from mouse pancreatic alpha cells. Diabetologia 2011;54:125–134
13. Cheng-Xue R, Gómez-Ruiz A, Antoine N, et al. Tolbutamide controls glucagon release from mouse islets differently than glucose: involvement of K$_{ATP}$ channels from both α-cells and β-cells. Diabetes 2013;62:1612–1622
14. Salehi A, Vieira E, Gyfle E. Paradoxical stimulation of glucagon secretion by high glucose concentrations. Diabetes 2006;55:2318–2323
15. Göpel S, Zhang Q, Eliasson L, et al. Capacitance measurements of exocytosis in mouse pancreatic α-, β- and δ-cells within intact islets of Langerhans. J Physiol 2004;556:711–726
16. Berts A, Gyfle E, Hellman B. Ca$^{2+}$ oscillations in pancreatic islet cells secreting glucagon and somatostatin. Biochem Biophys Res Commun 1995;208:644–649
17. Hellman B, Salehi A, Grapengiesser E, Gyfle E. Isolated mouse islets respond to glucose with an initial peak of glucagon release followed by pulses of insulin and somatostatin in antisynchrony with glucagon. Biochem Biophys Res Commun 2012;417:1219–1223
18. Hellman B, Salehi A, Gyfle E, Dansk H, Grapengiesser E. Glucose generates coincident insulin and somatostatin pulses and antisynchronous glucagon pulses from human pancreatic islets. Endocrinology 2009;150:5334–5340
19. Nadal A, Quesada I, Soria B. Homologous and heterologous asynchronicity between identified α-, β- and δ-cells within intact islets of Langerhans in the mouse. J Physiol 1999;517:85–93
20. Le Marchand SJ, Piston DW. Glucose suppression of glucagon secretion: metabolic and calcium responses from α-cells in intact mouse pancreatic islets. J Biol Chem 2010;285:14389–14398